

# SCIENTIFIC REPORTS



OPEN

## Two flagellar BAR domain proteins in *Trypanosoma brucei* with stage-specific regulation

Zdenka Cicova<sup>1</sup>, Mario Dejung<sup>2</sup>, Tomas Skalicky<sup>3</sup>, Nicole Eisenhuth<sup>1</sup>, Steffen Hanselmann<sup>1</sup>, Brooke Morriswood<sup>1</sup>, Luisa M. Figueiredo<sup>4</sup>, Falk Butter<sup>2</sup> & Christian J. Janzen<sup>1</sup>

Received: 17 June 2016  
Accepted: 03 October 2016  
Published: 25 October 2016

Trypanosomes are masters of adaptation to different host environments during their complex life cycle. Large-scale proteomic approaches provide information on changes at the cellular level, and in a systematic way. However, detailed work on single components is necessary to understand the adaptation mechanisms on a molecular level. Here, we have performed a detailed characterization of a bloodstream form (BSF) stage-specific putative flagellar host adaptation factor Tb927.11.2400, identified previously in a SILAC-based comparative proteome study. Tb927.11.2400 shares 38% amino acid identity with TbFlabarin (Tb927.11.2410), a procyclic form (PCF) stage-specific flagellar BAR domain protein. We named Tb927.11.2400 TbFlabarin-like (TbFlabarinL), and demonstrate that it originates from a gene duplication event, which occurred in the African trypanosomes. TbFlabarinL is not essential for the growth of the parasites under cell culture conditions and it is dispensable for developmental differentiation from BSF to the PCF *in vitro*. We generated TbFlabarinL-specific antibodies, and showed that it localizes in the flagellum. Co-immunoprecipitation experiments together with a biochemical cell fractionation suggest a dual association of TbFlabarinL with the flagellar membrane and the components of the paraflagellar rod.

The Kinetoplastida are a class of unicellular protists that share a common feature (the kinetoplast), comprising the mitochondrial DNA of the cell<sup>1</sup>. The class Kinetoplastida includes the order of exclusively parasitic Trypanosomatida, which are either monoxenous (restricted to one host individual), or dioxenous (undergoing a complex life cycle between a host and a vector). Some species of this order are the causative agents of various infectious diseases distributed in many parts of the world, with a devastating impact on human health and the economies of impoverished countries. For example, *Leishmania donovani* causes visceral leishmaniasis (Kala-Azar) in South and Central America, South Europe, Africa and West Asia; *Trypanosoma cruzi* causes Chagas disease in South America; *Trypanosoma brucei gambiense* and *Trypanosoma brucei rhodesiense* are responsible for sleeping sickness in humans (human African trypanosomiasis, HAT), and *Trypanosoma brucei brucei* causes nagana in livestock in sub-Saharan Africa<sup>2</sup>. Both *Leishmania* and the two *Trypanosoma* species are transmitted to mammals by bloodsucking insects.

*T. brucei* has developed a complicated life cycle with different developmental stages in order to proliferate in mammalian hosts and to use the tsetse fly for dissemination. The *T. brucei* parasites first proliferate in the blood and adipose tissue of infected mammals as a long slender (LS) bloodstream form (BSF)<sup>3</sup>. The surface of the BSF parasites is covered by a densely packed variant surface glycoprotein (VSG) coat, which is central to the antigenic variation mechanism contributing to host immune system evasion<sup>4</sup>. Upon accumulation of a quorum sensing signal called stumpy induction factor (SIF)<sup>5</sup>, LS parasites differentiate into a cell cycle-arrested short stumpy (SS) form, which are pre-adapted for further differentiation in the tsetse fly. In the fly midgut, the SS form differentiates into a dividing procyclic form (PCF), the surface of which is covered with procyclin<sup>6</sup>. While PCFs migrate from the midgut they further differentiate and colonize the salivary glands as epimastigotes. Epimastigote trypanosomes are able to attach to the host microvilli of the epithelial cells lining the salivary glands lumen by the

<sup>1</sup>Department of Cell & Developmental Biology, Biocenter, University of Würzburg, Würzburg, Germany. <sup>2</sup>Institute of Molecular Biology (IMB), Mainz, Germany. <sup>3</sup>Laboratory of Molecular Biology of Protists, Institute of Parasitology Biology Centre, Czech Academy of Science, and Faculty of Sciences, University of South Bohemia Ceske Budejovice, Czech Republic. <sup>4</sup>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa 1649-028, Portugal. Correspondence and requests for materials should be addressed to F.B. (email: f.butter@imb.de) or C.J.J. (email: christian.janzen@uni-wuerzburg.de)

flagellar membrane flagellipodia<sup>7</sup>. While still attached to the salivary gland surface, trypanosomes acquire the VSG coat and mature into metacyclics. These cells are preadapted for transfer to and life in the mammalian host when the fly takes a next blood meal and completes the life cycle of the parasite<sup>8</sup>.

The mammalian host and the tsetse fly vector represent two completely different environments in terms of host immune response challenges, energy resources and temperature. The parasite has developed a sophisticated adaptation strategy and adjusts its morphology, motility, metabolism, gene expression and organelle activity to survive and proliferate in these different host environments. More recently, it was shown that even within the mammalian host, the parasites adapt to the different tissues, as parasites in the blood and adipose tissue are functionally different<sup>3</sup>. Understanding the host adaptation mechanisms of *T. brucei* during its life cycle has been a challenging task for the field. Several genome-wide transcriptome analyses have been performed to elucidate how trypanosomes adapt to different host environments. In addition to the comparison of transcript abundance in PCF and BSF<sup>9</sup>, the transcriptome of differentiating parasites has been analyzed<sup>10,11</sup>.

These studies provided many insights into the adaptation machinery of trypanosomes but there are certain limitations to transcriptome-based approaches. Due to the fact that the regulation of gene expression in trypanosomes occurs almost exclusively post-transcriptionally—at the level of mRNA stability, translational efficiency, and protein stability—the levels of mRNA do not always reflect the actual protein abundance in the cell<sup>12</sup>. For example, transcriptome-wide quantification of mRNA stability revealed that highly abundant transcripts in BSF have longer half lives compared to the same transcripts in PCF<sup>13</sup>. Furthermore, translational efficiency in PCF and BSF varies greatly between these two life cycle stages as shown by ribosome profiling<sup>14,15</sup>.

Hence, proteome-based studies are required to completely understand how the parasite changes during developmental differentiation. Recently, stable isotope labeling (SILAC) was used to quantitatively compare the proteomes of BSF and PCF, which elucidated many new components of the machinery for adaptation to the insect and mammalian hosts<sup>16–18</sup>. A previous study from our laboratories elucidated many new components of the host adaptation machinery<sup>16</sup>. A total of 4364 protein groups were analyzed and many new putative proteins of unknown function were detected. In all, 625 protein groups were enriched in the PCF and 253 protein groups were enriched in the BSF<sup>16</sup>. Furthermore, we also used label-free mass spectrometry techniques to quantify changes of the trypanosome proteome during stage differentiation from the mammalian-infective to the insect form<sup>19</sup>. This study revealed many previously unknown components of the differentiation machinery that are involved in essential biological processes such as signaling, post-translational protein modifications, trafficking and nuclear transport.

Large-scale proteomic studies are extremely useful to approach cellular changes in a systematic way. However, to fully understand the functions and consequences of differential gene expression, detailed work on a molecular level is necessary. We therefore decided to specifically characterize putative proteins of unknown function that are highly upregulated in the BSF to learn more about novel trypanosomal adaptation factors for the mammalian host. We therefore focused on a well-investigated structure that is highly adapted to different host environments: the trypanosome flagellum.

Trypanosomes have a single flagellum attached lengthwise along the cell body. The flagellum contains a canonical eukaryotic axoneme and a paracrystalline accessory structure termed the paraflagellar rod (PFR)<sup>20,21</sup>. The flagellum emerges from the flagellar pocket (FP), an invagination of the cellular membrane and the exclusive site of exo- and endocytosis<sup>22,23</sup>. The axoneme is nucleated by a barrel-like microtubule structure called the basal body, which abuts the FP membrane, while the PFR is initiated once the flagellum has exited the FP<sup>24,25</sup>. The flagellum is attached to the body of the cell by a flagellar attachment zone (FAZ). The FAZ is a tripartite, trans-membrane adhesion complex that links the axoneme and PFR to two structures within the cell that run underneath the attached flagellum<sup>26–29</sup>. These structures are the FAZ filament and a specialized microtubule quartet. The composition of the flagellum has been investigated in several proteomic studies in PCFs<sup>30</sup>.

A growing body of evidence indicates that the flagellum is a major communication hub with the host environment, providing sensing and response to extracellular signals. A combination of flagellum purification together with affinity purification of surface-exposed proteins identified flagellum matrix and surface proteins in the BSF and gave an insight into flagellum signaling<sup>31</sup>. Stage-specific expression of individual paralogs within gene families was demonstrated by comparison of PCF and BSF cell surface proteomes, showing that the parasite surface is remodeled to allow adaptation to the different host environments<sup>32</sup>. The flagellar membrane is in direct contact with the outer environment. In the epimastigote form of the parasite, found in the tsetse fly, it forms branched flagellar outgrowths that are attached to the salivary gland epithelium<sup>33</sup>. PCF stage-specific flagellar surface receptor adenylate cyclases have been shown to localize specifically to the flagellum tip. This supports subdomain organization of the flagellar membrane and a microdomain model for flagellar cyclic AMP (cAMP) signaling in *T. brucei*<sup>34</sup>. Several other signaling molecules, virulence factors or potential motility factors from the flagellum such as BSF expression site associated gene ESAG4, metacaspase 4, glycosylphosphatidylinositol-phospholipase C and calflagins were reviewed previously<sup>34,35</sup>. Arginine kinase 3 (AK3) is highly expressed in PCF compared to BSF and was shown to confer advantage to the parasites during infection in tsetse flies<sup>36</sup>. Interestingly, AK3 shares a similarity with the flagellar targeting sequence of calflagins from *T. brucei* and flagellar calcium binding protein (FCaBP) from *T. cruzi*<sup>36</sup>. Recently, a study of several trypanosome species suggested that flagellar motion and swimming behavior restricts the parasite to distinguishable anatomic niches within the mammalian hosts<sup>37</sup>. Taken together, it is critical to learn more about flagellar composition and function to fully understand how these parasites adapt to different environments during their complicated life cycle.

Here we describe a putative flagellar component, Tb927.11.2400, which was discovered in our comparative proteome study<sup>16</sup>. Database searches revealed that Tb927.11.2400 shares 38% amino acid identity with PCF-specific TbFlabarin (Tb927.11.2410). Flabarin was initially described in *Leishmania donovani* as a flagellar BAR domain protein<sup>38</sup>. LdFlabarin is targeted to the flagellum by a potential N-terminal acylation site and has a central BAR domain for membrane association and a C-terminal domain needed for the flagellar specificity.

It forms a helicoidal structure from the base to the tip of the flagellum<sup>38</sup>. *In vitro* experiments suggest a morphogenetic and structural function since recombinant *LdFlabarin* associates with liposomes and triggers tubule formation<sup>38</sup>. We named Tb927.11.2400 *TbFlabarin-Like* (*TbFlabarinL*) following the convention adopted for *Flabarins*<sup>38</sup>. The two homologues in trypanosomes are likely a result of a gene duplication event. *TbFlabarinL* is downregulated 24 hours post induction of differentiation and undetectable in PCF. In contrast, *TbFlabarin* is upregulated very early during the differentiation process (2 h after induction) and is fully expressed 24 hours post induction. Protein expression levels of *TbFlabarinL* are 20-fold higher in BSF compared to PCF, which suggest that this protein might be a potential mammalian host-specific adaptation factor. We showed that *TbFlabarinL* is not essential for the growth of the parasite under cell culture conditions and that it is dispensable for developmental differentiation of trypanosomes. We generated a *TbFlabarinL* specific antibody and show that the endogenous protein localizes to the flagellum. We found that *TbFlabarinL* associates with both the flagellar membrane as well as with the PFR.

## Materials and Methods

**Computational analyses.** A BLAST search with *TbFlabarinL* (Tb927.11.2400) was performed against the TriTryp database<sup>39</sup>. Alignments were obtained from constraint-based multiple alignment tool (COBALT)<sup>40</sup> at the NCBI database and edited in Esprict 3.0<sup>41</sup>. Protein structures of *TbFlabarinL* and *TbFlabarin* were predicted by the Phyre2 server<sup>42</sup> and edited in UCSF Chimera 1.10.2<sup>43</sup>. Datasets for phylogenetic analyses were received from publicly available sources (Supplementary Table 1) for both *Flabarin* and *FlabarinL* genes, using BLASTP at an E-value cut-off of 10–20. All amino acid sequences were searched for conserved domains by Pfam. The datasets were aligned by MUSCLE and relevant positions were selected using Gblocks. Phylogenetic model selection with Modelgenerator favored LG + GAMMA model and ML trees were constructed using RAXML 8.1.17 with 1 000 bootstrap replicates. Bayesian Monte Carlo Markov (MCM) chain analysis was performed with GTR + GAMMA + CAT model using Phylobayes 3.3f running 8 independent chains for 10,000 cycles. Convergence of chains was estimated by comparison of bipartition frequencies in individual chains, discarding first 2,000 cycles.

**Trypanosome cell lines and cultivation.** Monomorphic BSF trypanosome “Single Marker” (SM) and 2T1 are both derivatives of Lister strain 427, antigenic type MITat 1.2, clone 221a (Doyle et al., 1980) and express T7 polymerase and Tetracycline repressor<sup>44</sup>. Monomorphic BSF trypanosomes were maintained in HMI-9 medium with 10% fetal calf serum (Sigma) and 5% CO<sub>2</sub><sup>45</sup>. PCF trypanosomes were cultured in modified SDM-79 medium with 10% fetal calf serum (Sigma) and 5% CO<sub>2</sub><sup>46</sup>. BSF and PCF cell densities were determined using a Coulter Counter Z2 (Beckman Coulter) particle counter, and cultures were diluted to maintain the cells in mid log growth phase. Transfection of monomorphic trypanosomes was performed as described previously<sup>47</sup>. Pleomorphic BSF trypanosomes AnTat1.1 were cultured in HMI-9 medium containing 1.1% methylcellulose. Cell density was determined using a Neubauer counting chamber (Brand) and cultures were diluted to maintain the cells in mid log growth phase. Cells were transfected as described previously<sup>48,49</sup>.

**Differentiation of trypanosomes.** Pleomorphic AnTat1.1 BSF were grown to a density of  $2.5 \times 10^6$  cells/ml, diluted 1:5 in TDB (5 mM KCl, 80 mM NaCl, 1 mM MgSO<sub>4</sub>, 20 mM Na<sub>2</sub>HPO<sub>4</sub>, 2 mM NaH<sub>2</sub>PO<sub>4</sub>, 20 mM glucose, pH 7.4), filtered, sedimented by centrifugation (1500 × g, 10 min, 37 °C) and resuspended to a cell density of  $2 \times 10^6$  cells/ml in DTM medium<sup>50</sup>. A mixture of cis-aconitate and isocitrate (3 mM) was added to induce differentiation and cells were incubated at 27 °C with 5% CO<sub>2</sub> as described previously<sup>50</sup>.

**Generation of transgenic trypanosome cell lines.** To generate the *TbFlabarinL*<sup>RNAi</sup> cell line, a DNA fragment (positions 30–544) was amplified from genomic DNA using a forward primer containing SmaI and XhoI restriction sites and a reverse primer containing BamHI and XbaI sites. Sense and antisense fragments of the RNAi hairpin were ligated into the pRPAiSL vector<sup>51</sup>. Prior to transfection of 2T1 cells, the plasmids were linearized using AscI. Clones with a correctly integrated construct were selected as described previously<sup>51</sup>. RNAi was induced by addition of 1 μg/ml tetracycline to the cell culture and refreshed daily.

A PCR-based gene deletion approach was used to sequentially replace both alleles of *TbFlabarinL* with puromycin N-acetyl-transferase (*PUR*) and hygromycin phosphotransferase (*HYG*) open reading frames (ORFs) in MiTat1.2 SM. The ends of the *TbFlabarinL* 5′ UTR (59 nt) and 3′ UTR (60 nt) were flanked by sequences to amplify the *HYG* and *PUR* ORFs from the pHD309 *HYG/PUR* plasmid (gift from G.A.M. Cross). Cells were electroporated with the purified PCR products. The same constructs were used to delete both *TbFlabarinL* alleles in AnTat1.1 and AnTat1.1E-SmOx cells. Correct integration of the constructs was verified by PCR using primers binding in the 5′ and 3′ UTR, 5′ and 3′ ORF and within the puromycin and hygromycin resistance ORFs (Supplementary Figs S3 and S4). PCR was performed according to the manufacturer’s instructions of the Phusion Human Specimen Direct PCR Kit (Thermo Fisher Scientific).

*TbFlabarinL* was epitope-tagged at the N- or C-terminus in the endogenous locus as described in ref. 52. The plasmids for tagging were kindly provided by S. Kramer, University of Würzburg. Briefly, the *TbFlabarinL* ORF fragment without stop codon was amplified from genomic DNA and cloned into p3077\_PAC\_4xTY plasmid. The vector was linearized within the ORF fragment by HpaI prior to transfection of the cells. To tag *TbFlabarinL* at the C-terminus, a part of the *TbFlabarinL* ORF (positions 2–653) was amplified from genomic DNA and cloned into p3074\_4xTY\_BLE plasmid and linearized by HpaI before transfection of the cells. The same strategy was used to tag *TbFlabarin* (Tb927.11.2410) at the C-terminus. A fragment of the *TbFlabarin* ORF (positions 1–666) was cloned into p3074\_4xTY\_BLE plasmid and linearized with BclI enzyme prior transfection. To tag PAR1 (Tb927.11.13500) at the N-terminus, a fragment (positions 4–823) of the PAR1 ORF was cloned into the p3077\_PAC\_4xTY plasmid and EcoRI was used for linearization.

To express *TbFlabarinL* in PCF ectopically, its ORF was amplified from genomic DNA and cloned into pLEW100v5b2x\_Phleo (gift from G.A.M. Cross) using XhoI and HindIII restriction sites. For ectopic expression of *TbFlabarin* in BSF, the *TbFlabarin* ORF was amplified from genomic DNA using a C-terminal primer containing a glycine-alanine-glycine (Gly-Ala-Gly) linker sequence followed by a Ty1-tag sequence and cloned into pLEW100v5b2x\_Phleo using XhoI and HindIII restriction sites. Constructs were linearized with NotI for integration into the ribosomal spacer locus. Expression was induced by addition of 1 µg/ml tetracycline to the cell culture.

**Polyclonal Antibody Generation.** The *TbFlabarinL* ORF was amplified from genomic DNA of *T. brucei* using a primer containing a 10x His-tag sequence and a Gly-Ala-Gly linker sequence and cloned into the pETDUET-1 vector (Novagen) using NcoI and XhoI restriction sites. *TbFlabarinL* was expressed in Rosetta Blue *Escherichia coli* according to the manufacturer's instructions and purified using an Äkta FPLC system with HisTrap FF crude 1 ml columns. Fractions containing recombinant *TbFlabarinL* were pooled, dialyzed in phosphate buffered saline and concentrated using a centrifugal filter unit with a 10 kDa cut off (Amicon). 1 mg of purified protein was sent to Pineda (Berlin) for antibody production. *TbFlabarinL*-specific antibody was affinity purified from the rabbit immune sera using the SulfoLink kit (Thermo Fisher Scientific) and recombinant *TbFlabarinL* according to the manufacturer's instructions. Antibody specificity was tested in immunoblots using recombinant *TbFlabarinL* and whole-cell lysates of wild-type,  $\Delta$ *TbFlabarinL* and *TbFlabarinL*<sup>RNai</sup> cell lines.

All primer sequences used in this study are available upon request.

**Western Blot (WB).** Whole-cell lysates were separated by SDS-PAGE on 10% polyacrylamide gels and transferred onto a Immobilon<sup>®</sup> PVDF membrane (MERCK MILLIPORE). The membrane was blocked 1 h at RT in PBS-5% milk and subsequently incubated 1 h at RT with polyclonal anti-*TbFlabarinL* rabbit antibody diluted 1:500 in PBS-1% milk. Monoclonal anti-PFR mouse antibody L13D6, monoclonal anti-tubulin TAT1 mouse antibody and BB2 anti-Ty1 mouse antibody were gifts from K. Gull (University of Oxford) and described elsewhere<sup>53–55</sup>. Anti-TbMORN1 rabbit antibody was described previously<sup>56</sup>. IRDye680- and IRDye800-coupled anti-mouse or anti-rabbit secondary antibodies were purchased from LI-COR Bioscience to detect the respective proteins with an Odyssey infrared imaging system (LICOR Bioscience).


**Immunofluorescence (IF).**  $1 \times 10^7$  cells were harvested by centrifugation (1500 × g, 10 min, RT) and resuspended in 1 ml TDB. Cells were fixed in 2% PFA (10 min, RT). After 3 wash steps in PBS, cells were settled onto Poly-L-lysine-coated slides (20 min, RT) and permeabilized using 0.2% IGEPAL in PBS (5 min, RT). Non-specific epitopes were blocked with 1% BSA in PBS (1 hr at 37 °C). Cells were incubated with the primary *TbFlabarinL* antibody diluted 1:200 in PBS-0.1% BSA and/or monoclonal BB2 anti-Ty1 mouse antibody diluted 1:500 in PBS-0.1% BSA (1 hr, RT). After washing with PBS, the secondary antibody was applied (Alexa 594 anti-mouse, Alexa 488 anti-rabbit (Life Technologies)) in PBS-0.1% BSA (30 min, RT). DNA was stained with 1 µg/ml 4,6-diamidino-2-phenylindole (DAPI) and cells were embedded in ProLong Gold Antifade (Molecular Probes) and imaged on Leica DMI 6000B microscope. Images were processed using Huygens Essential XII deconvolution software (Scientific Volume Imaging).

**Co-immunoprecipitation.** Polyclonal *TbFlabarinL* antibody was immobilized on protein G Sepharose Fast Flow beads (GE Healthcare). Non-specific binding was blocked (1 hr, 4 °C) with 0.5% BSA in 20 mM sodium phosphate buffer pH 7.0. Four biological replicates per cell line ( $2 \times 10^8$  cells each) were harvested by centrifugation (1500 × g, 10 min, 4 °C) and washed in TDB buffer. Cells were lysed in 400 µl IP buffer (150 mM NaCl, 20 mM Tris-HCl pH 8, 10 mM MgCl<sub>2</sub>, 0.25% IGEPAL 1 mM DTT, Protease Inhibitors Cocktail without EDTA (Roche)) by sonication using a Bioruptor (Diagenode) with a 3 cycles 30 s high power pulse with 30 s pause setting. Cell lysates were incubated with the blocked beads (orbital mixing, overnight, 4 °C). Beads were washed in IP buffer. To elute the proteins, beads were resuspended in 65 µl NuPAGE LDS Sample Buffer (Novex, Life Technologies) supplemented with 100 mM DTT and incubated 10 min at 70 °C. The eluates were analyzed by mass spectrometry.

**Mass Spectrometry.** Protein samples were separated on a 4–12% NuPAGE Gel (Life Technologies) and stained with Coomassie colloidal blue (Life Technologies). The lanes were sliced and prepared by in-gel digestion with trypsin<sup>57</sup>. The peptides were stored on StageTips. Digested peptides were separated on a C18 reverse phase column (packed in-house, 20 cm, 75 µm inner diameter; packed with repositilPur-1.8 [Dr. Maisch]) with a 105-minute gradient from 5 to 95 percent ACN on an Easy-nLC 1000. The solution was directly sprayed at 2.4 kV. The Q Exactive Plus was operated in a data-dependent Top10 acquisition mode with one full scan (70,000 resolution, max injection 20 ms, 300–1650 m/z) and up to 10 HCD fragment scans (17,500 resolution, max injection 120 ms). The raw spectra were analysed with MaxQuant ver1.5.1.0<sup>58</sup> using standard settings (except activated LFQ quantitation and match between runs) and the *Trypanosoma brucei* TriTrypDB-8.0\_TbruceiTREU927 database. The protein Groups file was filtered to exclude contaminants, reverse entries and proteins only identified by site prior to statistical analysis. To obtain enrichment the LFQ values were log<sub>2</sub> transformed and the mean between bait and control was calculated. To assess the statistical significance of the enrichment a Welch t-test for LFQ values between bait and control set was performed. Both values were visualized in a volcano plot using the ggplot2 package in R.

**Mouse experiments.** Animal experiments were performed according to EU regulations and approved by the Animal Ethics Committee of Instituto de Medicina Molecular (AEC\_2011\_006\_LF\_TBrucei\_IMM). Male C57BL/6 wild-type mice (Charles River) were housed in the pathogen-free mouse facility of the Instituto de Medicina Molecular (IMM) with a 12:12-h light:dark cycle. 6 weeks-old mice were used for intraperitoneal infection with  $2 \times 10^3$  parasites each. 5 mice were infected with *T. brucei* AnTat1.1E-SmOx parasites and 6 mice with





**Figure 1.** (A) Alignment of *TbFlabarinL* (Tb927.11.2400) with *TbFlabarin* (Tb927.11.2410). A BLAST search with the Tb927.11.2400 protein sequence identified a *Trypanosoma brucei* flabarin homologue (Tb927.11.2410). The amino acid sequences of *TbFlabarinL* and *TbFlabarin* have 38% identity (indicated by black boxes) and 60% similarity (indicated by white boxes). (B) Sequence-based structure modeling of *TbFlabarinL* and *TbFlabarin*. An overlay of the two structures is shown.


the  $\Delta$ *TbFlabarinL* cell line. Parasitemia was measured after infection by collecting blood from the tail vein. The vein was punctured with a gauge needle and 1  $\mu$ l of blood was collected and diluted in 149  $\mu$ l HMI-11. Parasites numbers were manually quantified using a Neubauer counting chamber. The minimum of detectable parasites in blood is  $1.5 \times 10^5$  cells/ml.

**Isolation of cytoskeletons and flagella.** Cytoskeleton- and flagella-enriched fractions were prepared following a published protocol<sup>59,60</sup> with minor modifications. Briefly,  $1 \times 10^8$  cells were harvested by centrifugation ( $1500 \times g$ , 10 min, 4 °C) and washed in 1 ml PEME buffer (2 mM EGTA, 1 mM MgSO<sub>4</sub>, 0.1 mM EDTA, 0.1 M piperazine-N,N'-bis (2-ethanesulfonic acid)-NaOH (PIPES-NaOH), pH 6.9). Cytoskeletons (P1) were obtained by extracting the cells in PEME buffer with 1% IGEPAL (15 min, RT, orbital mixing) and separated from the detergent soluble supernatant (S1) by centrifugation ( $3400 \times g$ , 5 min, 4 °C). Flagella were isolated from the extracted cytoskeletons (P1) by incubation in PEME buffer with 1% IGEPAL and 1M KCl (30 min, RT, orbital mixing), which depolymerized the corset microtubules, followed by centrifugation ( $6000 \times g$ , 15 min, 4 °C) to separate S2 and P2 fractions. All solutions were supplemented with Complete protease inhibitors cocktail without EDTA (Roche).


## Results

***TbFlabarinL* originated from a gene duplication event.** *TbFlabarinL* (Tb927.11.2400) was identified in a proteomic study<sup>16</sup> as a BSF-specific, putative protein of unknown function. A BLAST search in the TriTryp database<sup>39</sup> revealed a 38% amino acid (AA) identity and 60% similarity<sup>61,62</sup> to the product of the neighboring Tb927.11.2410 gene (Fig. 1A). Tb927.11.2410 is *TbFlabarin*, a flagellar BAR domain protein in *T. brucei*. Flabarins were first described in *Leishmania spp*<sup>38</sup>. *TbFlabarin* consists almost entirely of a BAR/IMD-like domain, which extends over the region of 8–212 AA out of a total 222 AA length of the protein. Despite the high similarity to *TbFlabarin* (60% AA similarity), a BAR/IMD like domain was not detected by the prediction software in *TbFlabarinL*. However, predicted structural models<sup>42</sup> of both *TbFlabarin* and *TbFlabarinL* feature a triple helix coiled coil architecture (Fig. 1B). Such a structure is characteristic of BAR proteins and enables formation of banana-shaped homo- or heterodimers known for their membrane curvature generation (reviewed in ref. 63).

*TbFlabarin* and *TbFlabarinL* are both found on chromosome 11 separated by an ~12 kb stretch of non-coding sequence. The *TbFlabarin* coding sequence (CDS) is on the complementary DNA strand. Orthologs of *TbFlabarinL* are present within the orthology group OG5\_185161 from Ortho MCL DB<sup>64,65</sup> in *T. brucei gambiense*, *T. vivax* and *T. evansi*. In contrast to Flabarin OG5\_148786, FlabarinL is neither present in the genomes of sequenced monoxenous (one-host) trypanosomatids, nor in the genus *Leishmania* and American trypanosomes. Phylogenetic analysis revealed a gene duplication event in African trypanosomes that gave rise to the FlabarinL



**Figure 2. Phylogenetic analysis of Flabarins across Trypanosomatida.** A maximum likelihood phylogenetic tree based on alignments of Flabarin and FlabarinL proteins. The scale bar indicates the inferred number of amino acid substitutions per site. The red dot indicates a gene duplication event that gave rise to the FlabarinL gene, which is present only in a subset of African trypanosomes.



**Figure 3. *TbFlabarinL* is a BSF stage-specific protein.** Immunoblot analysis of whole cell lysates from PCF and BSF cells using affinity purified anti-*TbFlabarinL* antibodies. Expression of *TbFlabarinL* was detected in BSF cells only. Immunoblotting with anti-Histone H3 served as a loading control. A representative blot of multiple ( $N > 3$ ) independent experiments is shown. Re: recombinant His-tagged *TbFlabarinL*.


gene (Fig. 2). Interestingly, FlabarinL is missing in *T. congolense* and *T. equiperdum*, which might be due to incompleteness of these genomes. On the other hand, it could reflect specific host adaptation requirements.

To confirm the expression profiles of the mass spectrometry study, we generated a *TbFlabarinL*-specific antibody. Recombinant full-length *TbFlabarinL* was purified from *E. coli* (Supplementary Fig. S1) and used for immunization of a rabbit. *TbFlabarinL*-specific antibody was affinity purified from the immune sera and used in Western blot (WB) analysis (Fig. 3). A band of the expected molecular weight could be detected in BSF whole cell lysates but not in lysates from PCF, supporting the conclusion from mass-spectrometry analysis that *TbFlabarinL* is a BSF stage-specific protein.

***TbFlabarinL* localizes to the flagellum in BSF trypanosomes.** *TbFlabarinL*-specific antibody was used in immunostaining to determine the subcellular localization of *TbFlabarinL* in BSF trypanosomes. A  $\Delta$ *TbFlabarinL* cell line (described in later sections) and PCF cells were used as controls. Cells were stained with *TbFlabarinL*-specific antibody and TAT1 anti-tubulin antibody (Fig. 4). *TbFlabarinL* localized to the flagellum in BSFs, with a labeling pattern that initiated close to the kinetoplast (small spot in DAPI channel) and extended lengthwise along the cell body. No signal was detected from the  $\Delta$ *TbFlabarinL* cells, confirming the specificity of the labeling pattern. No signal was detected in PCF cells, further confirming the stage-specific expression of the *TbFlabarinL* protein.

We observed that N-terminal tagging of *TbFlabarinL* resulted in a mislocalization of *TbFlabarinL*. Cells in which the ORF of only one allele was fused to a sequence that encodes for a 4xTy1 epitope tag by homologous





**Figure 6.** *TbFlabarin* and *TbFlabarinL* localization in the BSF and PCF *T. brucei*. Immunofluorescence staining using anti-Ty1 (red) and anti-*TbFlabarinL* (green) antibodies showed that ectopically expressed *TbFlabarin* in BSF had a similar patchy localization pattern as *TbFlabarinL*. The localization of the two proteins overlaps in some regions. **(B)** Ectopically expressed *TbFlabarinL* localized to the flagellum in PCF. **(C)** *In situ* C-terminally tagged *TbFlabarin* in PCF showed a similar localization pattern in the flagellum to the one of *TbFlabarinL* in BSF. Scale bar 3  $\mu\text{m}$ .


the flagellum (Fig. 6A). Conversely, ectopically overexpressed *TbFlabarinL* in PCF localized to the flagellum in a more continuous pattern along the whole length of the flagellum (Fig. 6B) presumably due to high expression levels (200-fold overexpression compared to endogenous protein levels in PCF). *In situ* C-terminally Ty1-tagged *TbFlabarin* in PCF localized to the flagellum and displayed a patchy pattern similar to that of *TbFlabarinL* in BSF (Fig. 6C). These observations are consistent with the hypothesis that *TbFlabarinL* and *TbFlabarin* have a similar stage-specific function in the flagellum of *T. brucei*.

***TbFlabarinL* is associated with the paraflagellar rod and the flagellar membrane.** To learn more about the function of *TbFlabarinL*, we employed a co-immunoprecipitation (IP) approach to find interacting partners of *TbFlabarinL*. Four biological replicates of WT and  $\Delta$ *TbFlabarinL* as a control were used in IP and analyzed by mass spectrometry. Two putative interacting partners Tb927.11.3840 and Tb927.11.13500 (Fig. 7A) were found. The first candidate interaction partner is an unknown putative protein with no conserved domains. The second candidate interaction partner is PAR1, a previously-described paraflagellar rod component<sup>67–69</sup>. To verify the result of the IP, an endogenous replacement cell line was generated by homologous recombination, with the PAR1 ORF fused to a sequence that encodes for a 4xTy1 epitope tag. These cells were stained with the anti-Ty1 antibody for immunolocalization studies. As expected, 4xTy1-PAR1 localized to the flagellum (Fig. 7B). Detection with anti-Ty1 and *TbFlabarinL* specific antibodies showed a partial overlap of *TbFlabarinL* and Ty1-PAR1 in distinct parts of the flagellum, which supported the result of the IP. Interestingly, *TbFlabarinL* localization revealed a different pattern compared to PAR1. *TbFlabarinL* showed an interrupted and punctate pattern throughout the flagellum (Fig. 7B).


The results of the IP experiment as well as the partial overlap of PAR1 and *TbFlabarinL* immunostaining imply a possible association of *TbFlabarinL* with the PFR structure of the flagellum. In contrast, the N-terminal sequence of *TbFlabarinL* seems to attach *TbFlabarinL* to the flagellar membrane. To probe the membrane association of *TbFlabarinL*, a biochemical cell fractionation was performed. In the first step, the detergent soluble fraction S1 (cytoplasm/membranes) was separated from P1 (cytoskeleton). In the second step, the cytoskeletal P1 fraction was treated with 1 M KCl to depolymerize the microtubule corset and the FAZ filament and thus separate S2 (corset microtubules together with FAZ) from P2 (PFR, axoneme, basal body and flagellar pocket collar). WB analysis of equal fractions (10% of input material) revealed that *TbFlabarinL* is found not only within the soluble cytoplasmic and membrane fractions but also within the cytoskeletal fractions both before and after separation of the flagella from the cytoskeleton (Fig. 8). This result supports the observations described in previous experiments, which suggested a dual interaction with the flagellar membrane as well as with structural components of the flagellum such as the PFR.

***TbFlabarinL* is not essential for BSF *in vitro* and *in vivo*.** In order to examine the effect of *TbFlabarinL* depletion on the viability of *T. brucei*, an inducible RNAi knockdown cell line was generated. *TbFlabarinL* expression was significantly reduced 24 h after induction and almost below detection level after 48 h (Fig. 9A). The growth of the parasites upon induction of RNAi was monitored. There was no growth phenotype observed






**B**



**Figure 7. Immunoprecipitation using *TbFlabarinL* specific antibody.** (A) Volcano plot of co-enriched proteins after anti-*TbFlabarinL* IP obtained by label-free quantitative mass spectrometry of four parallel biological replicates. Besides *TbFlabarinL* (Tb927.11.2400), two other proteins were enriched: Tb927.11.3840 and Tb927.11.13500. Tb927.11.3840 is an uncharacterized hypothetical protein. Tb927.11.13500 is PAR1, a paraflagellar rod component. (B) *TbFlabarinL* partially overlaps with the PFR component Par1 in the flagellum. Immunofluorescence analysis using the *TbFlabarinL* specific antibody showed that *TbFlabarinL* localized to the flagellum of *T. brucei*. A co-staining of the PFR component PAR1 (Ty1-tagged, red) and anti-*TbFlabarinL* (green) antibody showed *TbFlabarinL* and PAR1 overlap in certain regions of the flagellum. Scale bar 3  $\mu$ m.

upon depletion of *TbFlabarinL* in three independent clones (Fig. 9B and Supplementary Fig. S2), indicating that *TbFlabarinL* is not an essential gene for the survival of the parasite under cell culture conditions. To further pursue this indication, a  $\Delta$ *TbFlabarinL* knockout cell line was generated in BSF trypanosomes by homologous recombination. The deletion of both *TbFlabarinL* alleles was verified by integration PCR (Supplementary Fig. S3) and by WB analysis (Fig. 9C). No difference was observed in growth between the parental and the  $\Delta$ *TbFlabarinL* cell lines (Fig. 9D). To test the role of *TbFlabarinL* *in vivo*, we infected mice with WT and  $\Delta$ *TbFlabarinL* pleomorphic cell lines. We detected no significant differences between the parasitemia profiles and survival curves, suggesting that deletion of *TbFlabarinL* has no effect on mammalian infections (Fig. S6). We concluded that *TbFlabarinL* is not an essential gene for the viability of BSF *T. brucei* under cell culture conditions and *in vivo*.

***TbFlabarinL* is dispensable for developmental differentiation.** *TbFlabarinL* has a very interesting expression profile during developmental differentiation. It is highly upregulated in LS and SS forms, still detectable during early differentiation but is downregulated below detection levels 48 h after induction of




**Figure 8. Biochemical cell fractionation.** (A) Fractionation scheme: The input sample (I) was taken after non-ionic detergent extraction of BSF cells. The cells were then separated by centrifugation into a detergent-soluble supernatant (S1) and detergent-insoluble cytoskeletal pellet (P1). The P1 fraction was solubilized in high salt to depolymerize corset microtubules and further separated by centrifugation into supernatant (S2) and pellet (P2) fractions. (B) Fractionation of *TbFlabarinL*. Equal fractions (10%) were loaded on a gel and analyzed by immunoblotting. Anti-PFR, anti-tubulin and *TbFlabarinL* specific antibodies were used. *TbFlabarinL* was found in all fractions.

differentiation<sup>19</sup>. To test if *TbFlabarinL* could be involved in BSF to PCF transition, a stable  $\Delta$ *TbFlabarinL* cell line was generated in a pleomorphic *T. brucei* strain. So-called monomorphic parasites, which we used in the previous experiments, are culture adapted and very convenient for reverse genetics, but initiation of differentiation is inherently inefficient and asynchronous. In pleomorphic field strains of *T. brucei*, differentiation is very efficient and both steps of the differentiation process (LS to SS and SS to PCF) can be monitored in cell culture. Furthermore, pleomorphic strains still respond to stumpy induction factor (SIF) with growth arrest *in vivo* and are therefore the better system to study differentiation cell biology and virulence *in vivo*. Hence, we generated pleomorphic  $\Delta$ *TbFlabarinL* trypanosomes in strain AnTat1.1 as described above. The loss of both *TbFlabarinL* alleles was verified by integration PCR (Supplementary Fig. S4) and WB analysis (Fig. 10A). First, the growth of the  $\Delta$ *TbFlabarinL* cell line was compared to the parental cell line and only a mild growth phenotype was observed (Fig. 10B), which is in agreement with the result seen in the monomorphic  $\Delta$ *TbFlabarinL* cell line (Fig. 10). Second, the pleomorphic cells were grown to a high density to induce SS formation and then further differentiated for 52 hrs. WB analysis (Fig. 10C) confirmed the downregulation of *TbFlabarinL* during differentiation seen in proteomic analysis<sup>19</sup>.  $\Delta$ *TbFlabarinL* and parental cells grew equally well during developmental differentiation (Fig. 10D), which suggests that *TbFlabarinL* is dispensable for this process. A second very faint band migrating slightly higher than *TbFlabarinL* was detected by anti-*TbFlabarinL* antibody in the  $\Delta$ *TbFlabarinL* cell lines after induction of differentiation (Fig. 10C). The band is detectable in the WT pleomorphic cells during differentiation from SS to PCF at the time point 28 h post differentiation, when the *TbFlabarinL* band becomes weaker. The same band is detectable during the differentiation of  $\Delta$ *TbFlabarinL* at the time point 52 h. To exclude that the anti-*TbFlabarinL* antibody can recognize *TbFlabarin*, WB analysis of a BSF cell line ectopically expressing Ty1 epitope-tagged *TbFlabarin* was performed (Supplementary Fig. S5). Both anti-*TbFlabarinL* and anti-Ty1 antibody could only detect one band, which supports the specificity of the *TbFlabarinL*-specific antibody.

In summary, *TbFlabarinL* is a result of a gene duplication of *TbFlabarin*, which occurred in African trypanosomes. We generated a *TbFlabarinL* antibody and showed that it localizes to the flagellum. The results of IP experiments and a biochemical cell fractionation suggest a dual interaction of *TbFlabarinL* with the flagellar membrane as well as with structural components of the flagellum such as the PFR. *TbFlabarinL* is not essential for the growth and differentiation of *T. brucei* under cell culture conditions.

## Discussion


Trypanosomes must adapt to different host environments during their complex life cycle. Large-scale proteomic approaches provide information on changes at the cellular level in a systematic way. However, a detailed work on single components is necessary to understand the adaptation mechanisms on a molecular level. Here, we have performed a detailed characterization of a BSF stage-specific putative host adaptation factor Tb927.11.2400 identified in a SILAC-based comparative proteome study<sup>16</sup>. Tb927.11.2400 shares a 38% amino acid identity with *TbFlabarin* (Tb927.11.2410), a PCF stage-specific<sup>16</sup> flagellar BAR domain protein. The BAR domain is missed by the prediction software in Tb927.11.2400 and this is why we named it *TbFlabarin Like* (*TbFlabarinL*).



**Figure 9. Depletion of *TbFlabarinL* in BSF *T. brucei*.** (A) *TbFlabarinL* protein was almost undetectable 48 h after induction of RNAi, as determined by anti-*TbFlabarinL* immunoblot. A weak additional band with the size of 25 kDa is detectable after RNAi induction. PFR was used as a loading control. (B) Depletion of *TbFlabarinL* by RNAi had no effect on the growth of BSF *T. brucei* under cell culture conditions. A cumulative growth curve of one representative clone is shown. Two independent clones showed a similar phenotype (see Supplementary Fig. S2). (C) An immunoblot analysis using *TbFlabarinL* specific antibody confirmed deletion of *TbFlabarinL* in two independent clones (c1 and c2) and a non-clonal population (pool). A weak additional band with the size of 25 kDa is detectable after deletion of *TbFlabarinL*. Immunoblotting with anti-PFR antibodies was used as a loading control. (D) The  $\Delta$ *TbFlabarinL* cells showed no growth defect compared to the wild-type controls (N = 3).

Flabarin was first described in *L. donovani* as a flagellar BAR domain protein<sup>38</sup>. It forms a helical structure from the base to the tip of the flagellum<sup>38</sup>. *In vitro* experiments suggested a morphogenetic and structural function since recombinant *LdFlabarin* associates with liposomes and triggers tubule formation<sup>38</sup>. Recently, membranous nanotube formation was reported in *T. brucei*<sup>70</sup>. Those nanotubes appear to originate from the flagellar membrane and seem to dissociate into free extracellular vesicles (EVs). The protein composition of isolated EVs was determined by mass spectrometry and revealed the presence of *TbFlabarinL* together with 155 other proteins<sup>70</sup>. *TbFlabarinL* could be involved in nanotube/EVs formation or play a role in the fusion ability of the vesicles with other trypanosomes or erythrocytes or have an influence on the contents of the vesicles.

*TbFlabarinL* and *TbFlabarin* are both found adjacent on chromosome 11. We demonstrated that *TbFlabarinL* is a result of a gene duplication event that occurred in African trypanosomes. However, in *T. congolense* and *T. equiperdum* a secondary loss of FlabarinL seems to have happened. This could be explained by the unique life cycles of these two species. In contrast to *T. brucei*, *T. congolense* is a strictly intravascular parasite and does not traverse different tissues<sup>71</sup>. *T. equiperdum* is essentially a tissue parasite in the reproductive system of *Equidae* family animals with a very low parasitemia in the blood and is transmitted venereally<sup>72</sup>. A second reason for the absence of FlabarinL in *T. congolense* and *T. equiperdum* could be the limited sequencing data available for both species. While the BSF stage upregulation suggested an essential role of *TbFlabarinL* in the mammalian host, gene depletion and deletion experiments revealed that *TbFlabarinL* is not an essential gene for the growth and differentiation of trypanosomes in cell culture. Infections in mice indicated that *TbFlabarinL* is also dispensable *in vivo*. Based on the distribution of *TbFlabarinL* across the different trypanosomatida species, we speculate that *TbFlabarinL* was acquired as an adaptation to the lifestyle of different African trypanosomes, in particular to their ability to leave the bloodstream in the mammalian host and migrate through different tissues in the advanced stages of the infection. Alternatively, *TbFlabarinL* might be important for developmental differentiation in the Tsetse fly. Unfortunately, we do not have information about changes in expression levels of *TbFlabarinL* in different stages in the fly.



**Figure 10.** *TbFlabarinL* deletion in pleomorphic BSF *T. brucei*. (A) Immunoblot analysis with *TbFlabarinL* specific antibody verified the deletion of *TbFlabarinL*. An anti-PFR immunoblot was used as a loading control. (B) Deletion of *TbFlabarinL* causes a mild growth defect (N = 3). (C) Immunoblot analysis with *TbFlabarinL* specific antibody confirmed the downregulation of *TbFlabarinL* at different time points during differentiation from long slender (LS) to short stumpy (SS) and then 2, 28 and 52 hours after induction of differentiation. A weak additional band with the size of 25 kDa is detectable after induction of differentiation. (D) Pleomorphic trypanosomes were successfully differentiated from LS to PCF. There was no difference in the growth rate between the parental (WT) and  $\Delta$ *TbFlabarinL* cell line during and after differentiation (N = 1).

We generated a *TbFlabarinL*-specific antibody and could detect *TbFlabarinL* in the flagellum in a punctate pattern. Masking the N-terminal end of *TbFlabarinL* with an epitope tag resulted in mislocalization of the protein. This provided evidence for the importance of the N-terminal sequence in targeting *TbFlabarinL* to the flagellum. A closer inspection of the *TbFlabarinL* N-terminus allowed us to hypothesize that the presence of positively charged lysines and potentially myristoylated glycine and palmitoylated cysteine might be important for targeting *TbFlabarinL* to the flagellar membrane as shown previously for FCaBP in *T. cruzi*<sup>66</sup>. A recent study of the flagellar arginine kinase 3 (AK3) summarizes so far known proteins such as *TbCaf17*, *TbCaf24*, *TbCaf44* which all share similar flagellar address with the FCaBP<sup>36</sup>. In addition, the BAR domain of *LdFlabarin* mediates its association with the flagellar membrane<sup>38</sup>. A structural model of both *TbFlabarin* and *TbFlabarin* predicted a coiled-coil helical architecture identical with *LdFlabarin* despite a missing BAR domain *per se* and suggested a membrane association.

The punctate *TbFlabarinL* localization pattern could be explained by a potential association of the *TbFlabarinL* with discrete complexes in the flagellar membrane due to the presence of dual acylation. Dually acylated proteins have been shown to prefer association with membrane microdomains enriched in sphingolipids and cholesterol (reviewed in ref. 73). IP using anti-*TbFlabarinL* specific antibody identified PAR1 as a possible interacting partner of *TbFlabarinL*. PAR1 is a component of the PFR and unlike *TbFlabarinL*, it was detected in a comparative proteomic study<sup>74</sup> together with 20 novel components of the PFR. Cell fractionation revealed that *TbFlabarinL* is present not only in the detergent-soluble fraction but also it is tightly associated with the isolated flagella and cytoskeletal fractions containing the PFR, which is in concordance with the predicted flagellar membrane localization as well as the result of the IP experiment. We suggest that the association of *TbFlabarinL* with the flagellar membrane might be only transient and function via a myristoyl switch mechanism, where the exposure of the myristate moiety could be ligand mediated as it is in the case of ADP ribosylation factor 1 (Arf1)<sup>75</sup>. The binding of Arf1 to the membrane is regulated by guanine nucleotide (GDP). When GDP is bound, the myristoylated N-terminal helix is sheltered in a hydrophobic groove of Arf1 and dissociates from the membrane<sup>76</sup>. Likewise when a ligand binds to *TbFlabarinL*, it might dissociate from the membrane and interact with the cytoskeletal components of the flagellum. While this manuscript was in preparation, Tetaud and colleagues published the characterization of *TbFlabarin* in PCF<sup>77</sup>. They showed that *TbFlabarin* mRNA is mainly expressed in PCF and



that the flagellar localization of the protein is dependent on two cysteines at the N-terminus, which might mediate the strong association of the protein with the parasite's membrane in their palmitoylated form.

In this study we present a characterization of two flabarin orthologs in *T. brucei* with a major focus on *TbFlabarinL*, which is BSF stage specific in contrast to PCF specific *TbFlabarin*. Further research is still needed to fully understand the function of flabarins in trypanosomes.

## References

- Jensen, R. E. & Englund, P. T. Network news: the replication of kinetoplast DNA. *Annu. Rev. Microbiol.* **66**, 473–491 (2012).
- Lopes, A. H. *et al.* Trypanosomatids: Odd Organisms, Devastating Diseases. *Open Parasitol. J.* **4** (2010).
- Trindade, S. *et al.* Trypanosoma brucei Parasites Occupy and Functionally Adapt to the Adipose Tissue in Mice. *Cell Host Microbe* **19**, 837–848 (2016).
- Morrison, L. J., Marcello, L. & McCulloch, R. Antigenic variation in the African trypanosome: molecular mechanisms and phenotypic complexity. *Cell. Microbiol.* **11**, 1724–1734 (2009).
- Vassella, E., Reuner, B., Yutzy, B. & Boshart, M. Differentiation of African trypanosomes is controlled by a density sensing mechanism which signals cell cycle arrest via the cAMP pathway. *J. Cell Sci.* **110**, 2661–2671 (1997).
- Roditi, I. *et al.* Procyclin gene expression and loss of the variant surface glycoprotein during differentiation of Trypanosoma brucei. *J. Cell Biol.* **108**, 737–746 (1989).
- Tetley, L. & Vickerman, K. Differentiation in Trypanosoma brucei: host-parasite cell junctions and their persistence during acquisition of the variable antigen coat. *J. Cell Sci.* **74**, 1–19 (1985).
- Vickerman, K. Developmental cycles and biology of pathogenic trypanosomes. *Br. Med. Bull.* **41**, 105–114 (1985).
- Siegel, T. N., Hekstra, D. R., Wang, X., Dewell, S. & Cross, G. A. M. Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. *Nucleic Acids Res.* **38**, 4946–4957 (2010).
- Queiroz, R., Benz, C., Fellenberg, K., Hoheisel, J. D. & Clayton, C. Transcriptome analysis of differentiating trypanosomes reveals the existence of multiple post-transcriptional regulons. *BMC Genomics* **10**, 495 (2009).
- Kabani, S. *et al.* Genome-wide expression profiling of *in vivo*-derived bloodstream parasite stages and dynamic analysis of mRNA alterations during synchronous differentiation in Trypanosoma brucei. *BMC Genomics* **10**, 427 (2009).
- Clayton, C. The regulation of trypanosome gene expression by RNA-binding proteins. *PLoS Pathog.* **9**, e1003680 (2013).
- Manful, T., Fadda, A. & Clayton, C. The role of the 5'-3' exoribonuclease XRNA in transcriptome-wide mRNA degradation. *RNA* **17**, 2039–2047 (2011).
- Vasquez, J.-J., Hon, C.-C., Vanselow, J. T., Schlosser, A. & Siegel, T. N. Comparative ribosome profiling reveals extensive translational complexity in different Trypanosoma brucei life cycle stages. *Nucleic Acids Res.* **42**, 3623–3637 (2014).
- Jensen, B. C. *et al.* Extensive stage-regulation of translation revealed by ribosome profiling of Trypanosoma brucei. *BMC Genomics* **15**, 911 (2014).
- Butter, F. *et al.* Comparative proteomics of two life cycle stages of stable isotope-labeled Trypanosoma brucei reveals novel components of the parasite's host adaptation machinery. *Molecular & Cellular Proteomics* **12**, 172–179 (2012).
- Gunasekera, K., Wüthrich, D., Braga-Lagache, S., Heller, M. & Ochsenreiter, T. Proteome remodelling during development from blood to insect-form Trypanosoma brucei quantified by SILAC and mass spectrometry. *BMC Genomics* **13**, 556 (2012).
- Urbaniak, M. D., Guthrie, M. L. S. & Ferguson, M. A. J. Comparative SILAC proteomic analysis of Trypanosoma brucei bloodstream and procyclic lifecycle stages. *PLoS One* **7**, e36619 (2012).
- Dejung, M. *et al.* Quantitative Proteomics Uncovers Novel Factors Involved in Developmental Differentiation of Trypanosoma brucei. *PLoS Pathog.* **12**, e1005439 (2016).
- Wheeler, R. J., Gluenz, E. & Gull, K. The limits on trypanosomatid morphological diversity. *PLoS One* **8**, e79581 (2013).
- Gull, K. The cytoskeleton of trypanosomatid parasites. *Annu. Rev. Microbiol.* **53**, 629–655 (1999).
- Engstler, M. *et al.* Kinetics of endocytosis and recycling of the GPI-anchored variant surface glycoprotein in Trypanosoma brucei. *J. Cell Sci.* **117**, 1105–1115 (2004).
- Grünfelder, C. G. *et al.* Endocytosis of a glycosylphosphatidylinositol-anchored protein via clathrin-coated vesicles, sorting by default in endosomes, and exocytosis via RAB11-positive carriers. *Mol. Biol. Cell* **14**, 2029–2040 (2003).
- Lacomble, S. *et al.* Basal body movements orchestrate membrane organelle division and cell morphogenesis in Trypanosoma brucei. *J. Cell Sci.* **123**, 2884–2891 (2010).
- Lacomble, S. *et al.* Three-dimensional cellular architecture of the flagellar pocket and associated cytoskeleton in trypanosomes revealed by electron microscope tomography. *J. Cell Sci.* **122**, 1081–1090 (2009).
- Vaughan, S., Kohl, L., Ngai, I., Wheeler, R. J. & Gull, K. A repetitive protein essential for the flagellum attachment zone filament structure and function in Trypanosoma brucei. *Protist* **159**, 127–136 (2008).
- Sunter, J. D., Varga, V., Dean, S. & Gull, K. A dynamic coordination of flagellum and cytoplasmic cytoskeleton assembly specifies cell morphogenesis in trypanosomes. *J. Cell Sci.* **128**, 1580–1594 (2015).
- Zhou, Q., Hu, H., He, C. Y. & Li, Z. Assembly and maintenance of the flagellum attachment zone filament in Trypanosoma brucei. *J. Cell Sci.* **128**, 2361–2372 (2015).
- Sunter, J. D. & Gull, K. The Flagellum Attachment Zone: 'The Cellular Ruler' of Trypanosome Morphology. *Trends Parasitol.* **32**, 309–324 (2016).
- Subota, I. *et al.* Proteomic analysis of intact flagella of procyclic Trypanosoma brucei cells identifies novel flagellar proteins with unique sub-localization and dynamics. *Mol. Cell. Proteomics* **13**, 1769–1786 (2014).
- Oberholzer, M. *et al.* Independent analysis of the flagellum surface and matrix proteomes provides insight into flagellum signaling in mammalian-infectious Trypanosoma brucei. *Mol. Cell. Proteomics* **10**, M111.010538 (2011).
- Shimogawa, M. M. *et al.* Cell surface proteomics provides insight into stage-specific remodeling of the host-parasite interface in Trypanosoma brucei. *Mol. Cell. Proteomics* M114.045146 (2015).
- Tetley, L. & Vickerman, K. Differentiation in Trypanosoma brucei: host-parasite cell junctions and their persistence during acquisition of the variable antigen coat. *J. Cell Sci.* **74**, 1–19 (1985).
- Saada, E. A. *et al.* Insect stage-specific receptor adenylate cyclases are localized to distinct subdomains of the Trypanosoma brucei Flagellar membrane. *Eukaryot. Cell* **13**, 1064–1076 (2014).
- Langousis, G. & Hill, K. L. Motility and more: the flagellum of Trypanosoma brucei. *Nat. Rev. Microbiol.* **12**, 505–518 (2014).
- Ooi, C.-P. *et al.* The Flagellar Arginine Kinase in Trypanosoma brucei Is Important for Infection in Tsetse Flies. *PLoS One* **10**, e0133676 (2015).
- Bargul, J. L. *et al.* Species-Specific Adaptations of Trypanosome Morphology and Motility to the Mammalian Host. *PLoS Pathog.* **12**, e1005448 (2016).
- Lefebvre, M. *et al.* LdFlabarin, a new BAR domain membrane protein of Leishmania flagellum. *PLoS One* **8**, e76380 (2013).
- Aslett, M. *et al.* TriTrypDB: a functional genomic resource for the Trypanosomatidae. *Nucleic Acids Res.* **38**, D457–D462 (2010).
- Papadopoulos, J. S. & Agarwala, R. COBALT: constraint-based alignment tool for multiple protein sequences. *Bioinformatics* **23**, 1073–1079 (2007).

41. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res.* **42**, W320–W324 (2014).
42. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. E. The Phyre2 web portal for protein modeling, prediction and analysis. *Nat. Protoc.* **10**, 845–858 (2015).
43. Pettersen, E. F. *et al.* UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004).
44. Wirtz, E., Leal, S., Ochatt, C. & Cross, G. M. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **99**, 89–101 (1999).
45. Hirumi, H. & Hirumi, K. Continuous cultivation of *Trypanosoma brucei* blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. *J. Parasitol.* **75**, 985–989 (1989).
46. Brun, R. & Schönenberger. Cultivation and *in vitro* cloning or procyclic culture forms of *Trypanosoma brucei* in a semi-defined medium. Short communication. *Acta Trop.* **36**, 289–292 (1979).
47. Burkard, G., Frago, C. M. & Roditi, I. Highly efficient stable transformation of bloodstream forms of *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **153**, 220–223 (2007).
48. Vassella, E. *et al.* Deletion of a novel protein kinase with PX and FYVE-related domains increases the rate of differentiation of *Trypanosoma brucei*. *Mol. Microbiol.* **41**, 33–46 (2001).
49. MacGregor, P., Rojas, F., Dean, S. & Matthews, K. R. Stable transformation of pleomorphic bloodstream form *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **190**, 60–62 (2013).
50. Overath, P., Czichos, J. & Haas, C. The effect of citrate/ cis-aconitate on oxidative metabolism during transformation of *Trypanosoma brucei*. *Eur. J. Biochem.* **160**, 175–182 (1986).
51. Alsford, S. & Horn, D. Single-locus targeting constructs for reliable regulated RNAi and transgene expression in *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **161**, 76–79 (2008).
52. Kelly, S. *et al.* Functional genomics in *Trypanosoma brucei*: A collection of vectors for the expression of tagged proteins from endogenous and ectopic gene loci. *Mol. Biochem. Parasitol.* **154**, 103–109 (2007).
53. Kohl, L., Sherwin, T. & Gull, K. Assembly of the paraflagellar rod and the flagellum attachment zone complex during the *Trypanosoma brucei* cell cycle. *J. Eukaryot. Microbiol.* **46**, 105–109 (1999).
54. Woods, A. *et al.* Definition of individual components within the cytoskeleton of *Trypanosoma brucei* by a library of monoclonal antibodies. *J. Cell Sci.* **93**, 491–500 (1989).
55. Bastin, P., Bagherzadeh, A., Matthews, K. R. & Gull, K. A novel epitope tag system to study protein targeting and organelle biogenesis in *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **77**, 235–239 (1996).
56. Morriswood, B. *et al.* Novel bilobe components in *Trypanosoma brucei* identified using proximity-dependent biotinylation. *Eukaryot. Cell* **12**, 356–367 (2013).
57. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V. & Mann, M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat. Protoc.* **1**, 2856–2860 (2006).
58. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**, 1367–1372 (2008).
59. Esson, H. J. *et al.* Morphology of the trypanosome bilobe, a novel cytoskeletal structure. *Eukaryot. Cell* **11**, 761–772 (2012).
60. Morriswood, B. & Schmidt, K. A MORN-repeat protein facilitates protein entry into the flagellar pocket of *Trypanosoma brucei*. *Eukaryot. Cell* **15**, 00094–15 (2015).
61. Schäffer, A. A. *et al.* Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. *Nucleic Acids Res.* **29**, 2994–3005 (2001).
62. Altschul, S. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* **25**, 3389–3402 (1997).
63. Mim, C. & Unger, V. M. Membrane curvature and its generation by BAR proteins. *Trends Biochem. Sci.* **37**, 526–533 (2012).
64. Li, L., Stoeckert, C. J. & Roos, D. S. OrthoMCL: identification of ortholog groups for eukaryotic genomes. *Genome Res.* **13**, 2178–2189 (2003).
65. Chen, F., Mackey, A. J., Stoeckert, C. J. & Roos, D. S. OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups. *Nucleic Acids Res.* **34**, D363–D368 (2006).
66. Maric, D. *et al.* Molecular determinants of ciliary membrane localization of *Trypanosoma cruzi* flagellar calcium-binding protein. *J. Biol. Chem.* **286**, 33109–33117 (2011).
67. Saborio, J. L. *et al.* Isolation and characterization of paraflagellar proteins from *Trypanosoma cruzi*. *J. Biol. Chem.* **264**, 4071–4075 (1989).
68. Fouts, D. L. *et al.* Evidence for Four Distinct Major Protein Components in the Paraflagellar Rod of *Trypanosoma cruzi*. *J. Biol. Chem.* **273**, 21846–21855 (1998).
69. Lacomble, S., Portman, N. & Gull, K. A protein-protein interaction map of the *Trypanosoma brucei* paraflagellar rod. *PLoS One* **4**, e7685 (2009).
70. Szempruch, A. J. *et al.* Extracellular Vesicles from *Trypanosoma brucei* Mediate Virulence Factor Transfer and Cause Host Anemia. *Cell* **164**, 246–257 (2016).
71. Banks, K. L. Binding of *Trypanosoma congolense* to the Walls of Small Blood Vessels\*. *J. Protozool.* **25**, 241–245 (1978).
72. Claes, F., Büscher, P., Touratier, L. & Goddeeris, B. M. *Trypanosoma equiperdum*: master of disguise or historical mistake? *Trends Parasitol.* **21**, 316–321 (2005).
73. Resh, M. D. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. *Biochim. Biophys. Acta–Mol. Cell Res.* **1451**, 1–16 (1999).
74. Portman, N., Lacomble, S., Thomas, B., McKean, P. G. & Gull, K. Combining RNA interference mutants and comparative proteomics to identify protein components and dependences in a eukaryotic flagellum. *J. Biol. Chem.* **284**, 5610–5619 (2009).
75. Boman, A. & Kahn, R. Arf proteins: the membrane traffic police? *Trends Biochem. Sci.* **20**, 147–150 (1995).
76. Amor, J. C., Harrison, D. H., Kahn, R. A. & Ringe, D. Structure of the human ADP-ribosylation factor 1 complexed with GDP. *Nature* **372**, 704–708 (1994).
77. Tetaud, E. *et al.* TbFlabarin, a flagellar protein of *Trypanosoma brucei*, highlights differences between *Leishmania* and *Trypanosoma* flagellar-targeting signals. *Exp. Parasitol.* **166**, 97–107 (2016).

## Acknowledgements

We thank Elisabeth Kremmer and Keith Gull for providing antibodies and Nicolai Siegel for helpful discussion and critical reading of the manuscript. We thank Margarida Vaz and Fabien Guegan for assistance with the mouse experiments and transfections.

## Author Contributions

Z.D., N.E. and S.H. performed the experiments and prepared the Figures 3–7, 9 and 10. M.D. and F.B. performed and analyzed the mass spectrometry experiments. T.S. contributed the phylogenetic analysis. B.M. contributed the cell fractionation experiment. L.M.F., F.B. and C.J.J. wrote the manuscript and supervised the study.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Cicova, Z. *et al.* Two flagellar BAR domain proteins in *Trypanosoma brucei* with stage-specific regulation. *Sci. Rep.* **6**, 35826; doi: 10.1038/srep35826 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016